39 results about "Infectious gastroenteritis" patented technology

The invention discloses a medicinal composition for treating infectious gastroenteritis of a piglet. The medicinal composition includes the following constituents: 50-70 parts of pericarpium granati, 50-70 parts of ciliatenerve knotweed roots, 50-70 parts of flos hibisci, 40-60 parts of pulsatilla chinensis, 40-60 parts of sargentodoxa cuneata, 40-60 parts of patrinia villosa juss, 40-60 parts of fried coix seeds, 30-50 parts of dendranthema indicum, 30-50 parts of acalypha australis, 20-40 parts of agrimonia pilosa, 3-7 parts of berberine powder, 3-7 parts of piglet special bacteria and 3-7 parts of vitamin B complex. Through organic combination, dialectical compatibility and mutual assistance of the constituents, the functions of the medicinal composition for clearing heat, drying dampness and curing diarrhea is strengthened, and the purpose of curing diarrhea of the piglet is achieved; the medicinal composition can effectively prevent the piglet from suffering infectious gastroenteritis, is safe and nontoxic with a definite curative effect, and can improve the immunity of animals and the breeding benefit. Clinical trials prove that the cure rate of the medicinal composition for piglet diarrhea is 93.15%, with an effective rate of 98.97%.

The invention relates to a porcine interferon-gamma composite medicament and application thereof, belonging to the technical field of rear livestock medicaments. Per liter of porcine interferon-gamma composite medicament injection is prepared from the following raw materials: 400-500ml of porcine interferon-gamma, 100-180g of astragalus mongholicus extract, 100-180g of golden cypress extract, 100-180g of coptis extract, 20-30g of codonopsis extract, 40-80g of licorice extract and 2-8g of bursin. The porcine interferon-gamma composite medicament injection has a good effect in the processes of treating and preventing piglet infectious gastroenteritis and pig epidemic diarrhea, and the effective prevention rate is above 85%.

The invention discloses an application of recombinant salmonella containing nucleotide sequences shown in SEQ ID NO: 1 and SEQ ID NO: 2 in preparation for a medicine for preventing swine transmissible gastroenteritis, and further discloses a vaccine for preventing swine transmissible gastroenteritis, which is prepared from recombinant salmonella containing nucleotide sequences shown in SEQ ID NO: 1 and SEQ ID NO: 2, and pharmaceutically acceptable auxiliary materials or carriers. The vaccine disclosed by the invention is capable of inducibly producing two specific antibodies with regard to the S-protein and the N-protein of swine transmissible gastroenteritis virus (TGEV) simultaneously, has a double-gene immunologic function, a more comprehensive immunologic effect and a high level of the induced antibodies, as well as is capable of providing a more comprehensive protection function for swine transmissible gastroenteritis and excellent in clinical application prospect.

The invention discloses a low virulent strain HB08 of a porcine transmissible gastroenteritis virus (TGEV) and an application thereof. The microbial collection number of the low virulent strain is CGMCC No.7807. The low virulent strain of the TGEV is good in safety, and the virulent strain is safe to the pigs of all ages including pregnant sows and piglets. The low virulent strain has 100% active protection rate and 97.2% passive protection rate on three-day-old piglets, therefore, the low virulent strain HB08 of the porcine transmissible gastroenteritis virus is indicated to have excellent immunoprotection effect on the porcine transmissible gastroenteritis.

The present invention relates to a method for measuring the titer of N protein antibody of porcine transmissible gastroenteritis virus, comprising the following steps: S1, experimental animal immunity test; including N protein immunization of Bactrian camels and N protein antibody titer; S2, constructing VHH Phage library; including amplification of VHH gene and display vector construction and nanobody library construction and library capacity determination; S3, panning N-specific nanobodies; including library rescue and recombinant phage titer determination, panning N protein-specific recombination Phage, protein-specific recombinant phage enrichment and crude extract preparation and ELISA detection of N protein recombinant nanobody.

The invention provides a method for expressing the recombinant Lactococcus lactis of porcine transmissible gastroenteristis virus (Transmissible gastroenteristisvirus, TGEV) spike S protein. According to the complete gene sequence of the porcine transmissible gastroenteritis virus S protein and the gene fusion characteristics of the expression vector plasmid, a pair of primers were designed and PCR was carried out to obtain a 2007bp target fragment containing the four main antigenic sites of the TGEV S gene, which was combined with The vector plasmid pNZ8112 for secreted expression was connected, and transformed into host bacteria Lactococcus lactis NZ9000 cells by electrotransformation, and expressed under the induction of nisin. In the present invention, a coronavirus TGEV S protein Lactococcus lactis expression vector system is constructed, and the target protein of about 66KDa containing four main antigenic sites of TGEV S protein A, B, C, and D is expressed, and western blot experiments and indirect immunofluorescence The tests all showed that the expressed foreign protein could react with TGEV immune serum, indicating that the recombinant S protein had the same antigenicity as the TGEV natural antigen.

Medicine for treating animal enterogastritis and its preparing method, wherein the medicine is prepared from andrographolide, Mequindoc, berberine,atropine, trimethoprim, sodium salicylate propylene glycol through extraction, filtering, lixiviating, concentrating, mixing, stirring, sterilizing, loading and printing.

The present invention provides a freeze-dried protective agent for porcine infectious gastroenteritis and porcine epidemic diarrhea combined live vaccine and a combined live vaccine. , gelatin 6-10%, tryptone 2-6%, yeast extract powder 1-3%, chondroitin sulfate 0.1-2% and inositol 1-5%, the balance is water for injection, and the unit of mass-volume ratio is g / ml, the dual live vaccine includes the freeze-drying protective agent, which can effectively solve the problems of the existing freeze-dried products having depressions and cracks on the surface, slow dissolving speed of the freeze-dried products and loss of titer after freeze-drying.

The invention relates to a porcine interferon-gamma composite medicament and application thereof, belonging to the technical field of rear livestock medicaments. Per liter of porcine interferon-gamma composite medicament injection is prepared from the following raw materials: 400-500ml of porcine interferon-gamma, 100-180g of astragalus mongholicus extract, 100-180g of golden cypress extract, 100-180g of coptis extract, 20-30g of codonopsis extract, 40-80g of licorice extract and 2-8g of bursin. The porcine interferon-gamma composite medicament injection has a good effect in the processes of treating and preventing piglet infectious gastroenteritis and pig epidemic diarrhea, and the effective prevention rate is above 85%.

The invention discloses the application of all-trans retinoic acid in the preparation of an anti-porcine infectious gastroenteritis virus drug. Acid mainly exerts its antiviral effect by inhibiting the replication of porcine infectious gastroenteritis virus. As the concentration of all-trans retinoic acid increases, the inhibitory effect is more obvious. It is safe and toxic for anti-porcine infectious gastroenteritis virus. It has few side effects, is easily metabolized and absorbed by the animal body, and the animal waste does not pollute the environment.

The invention relates to a porcine transmissible gastroenteritis virus yolk antibody and a preparation method thereof. A hen immunized with an inactivated porcine transmissible gastroenteritis virus TGEV-BD strain having a preservation number of CGMCC No. 13856 is employed, and the yolk antibody is extracted and purified from egg yolks of the hen. The porcine transmissible gastroenteritis virus yolk antibody prepared by adopting the method has the advantages of safety, high specificity, good treatment effect, low production cost, etc., and can effectively prevent and treat diseases caused by porcine transmissible gastroenteritis virus, and has good application prospect.

The present invention relates to a porcine transmissible gastroenteritis virus antibody detection kit, the detection method is competition ELISA, the kit uses the protein of the amino acid sequence shown in SEQ ID No.1 as the competitive antibody in the detection reagent, and the Anti-N protein antibodies compete for binding to N protein. The results of the antiviral test showed that when the inoculated dose was 0.01 MOI, the nanobodies all showed inhibitory effect on virus replication on ST cells.

A recombinant Lactococcus lactis expressing and secreting anti-porcine transmissible gastroenteritis virus single-chain antibody and its preparation method. A fusion sequence, the fusion sequence has the amino acid sequence shown in SEQ ID No.4. The single-chain antibody secreted by the recombinant Lactococcus lactis can specifically bind to the porcine transmissible gastroenteritis virus, and can be used to block the infection of the porcine transmissible gastroenteritis virus and provide protection for piglets infected with the virus.

The invention relates to Shuanghuanglian for injection as a compound preparation of traditional Chinese veterinary medicine and its preparation process and application. The compound preparation of the present invention is prepared from the following medicines in parts by weight: 1250-3750 parts of honeysuckle, 1250-3750 parts of scutellaria baicalensis and 2500-7500 parts of forsythia. Sustained-release excipients are 200 parts of hydroxypropylmethylcellulose and 100 parts of sodium carboxymethylcellulose. Because it contains slow-release excipients, it can reduce the number of injections for large animals and reduce the stress response of large animals. The veterinary traditional Chinese medicine injection preparation of the invention has the effects of antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, and improving immunity. Its veterinary medicine can be used for coughs caused by epidemic diarrhea, infectious gastroenteritis, piglet paratyphoid, sepsis caused by various epidemic diseases, streptococcal disease, haemophilus parasuis, infectious pleuropneumonia, swine lung disease, etc. , dyspnea, cyanosis of the skin, joint swelling, lameness, porcine reproductive and respiratory syndrome, mastitis of cows.